Navigation Links
Researchers Find High-Dose Therapy for Liver Disease Not Effective
Date:8/28/2009

High-dose ursodeoxycholic acid detrimental for treatment of primary sclerosing cholangitis

ROCHESTER, Minn., Aug. 28 /PRNewswire-USNewswire/ -- A national team of researchers led by scientists at Mayo Clinic has found that a common treatment for primary sclerosing cholangitis, a chronic liver disease, is not helpful for patients, according to a study published this month in the journal Hepatology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090105/MAYOLOGO )

Primary sclerosing cholangitis (PSC) is a disease of the bile ducts. In this case, the term "cholangitis" refers to inflammation of the bile ducts, while "sclerosing" describes the hardening and scarring of the bile ducts that result from chronic inflammation.

"Primary sclerosing cholangitis is a serious liver disease lacking an effective medical therapy," says Keith Lindor, M.D., Mayo Clinic gastroenterologist and the study's lead researcher. "Some studies have shown that the use of ursodeoxycholic acid, a naturally occurring bile acid, may be a potential solution for patients. Our research, however, showed long-term use of this treatment in high dosages is not suitable for patients."

In this six-year, multicenter trial, 150 patients were enrolled in the study to determine the effectiveness of ursodeoxycholic acid (UDCA) in treatment of PSC. Seventy-six patients were treated with higher doses (2
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nucleix Researchers Discover DNA Evidence May Easily Be Falsified
2. Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
3. Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
4. Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students
5. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
6. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
7. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
8. Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD)
9. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
10. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
11. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Utah , Aug. 29, 2014  BC Technical, ... has acquired Polaris Medical Imaging, a leader in sales, ... This strategic acquisition allows BC Technical to continue to ... specifically within MR and CT modalities. ... service," said Mark Alvarez , president and CEO ...
(Date:8/29/2014)... -- Research and Markets has announced the ... & Pipeline Insight 2014" report to their offering. ... and eradicate the prevalence of cancer have achieved limited ... low specificity, safety and large number of side effects, ... solution. It has been discovered that peptides can be ...
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... 4 Shire plc ... biopharmaceutical company, today announced that the US Food and ... information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) ... CII, to include supplemental data demonstrating significant improvement in ...
... , May 4 Kaiser Permanente, committed to improving the ... require suppliers to provide environmental data for $1 billion worth ... other facilities. , , , ... Scorecard is the first of its kind in health care. It will ...
Cached Medicine Technology:FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 2FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 3FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 5FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 6FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 7FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 8Kaiser Permanente Launches Sustainability Scorecard for Medical Products 2Kaiser Permanente Launches Sustainability Scorecard for Medical Products 3
(Date:9/1/2014)... Mass., (PRWEB) September 01, 2014 BCC ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , ... $21.8 million in 2013 and is expected to reach ... grow to $471.5 million by 2019, which is equivalent ... through 2019. The receptor-mediated transport (RMT) segment is forecasted ...
(Date:9/1/2014)... NJ (PRWEB) September 01, 2014 Registration is ... The Warriors® 5K and 1-Mile Race to be held on ... The Plaza Court Yard at Harmon Meadow in Secaucus, New ... The Warriors®, a national nonprofit dedicated to restoring a sense ... our service members and our military families. , General registration ...
(Date:9/1/2014)... Outlier Series announced the next short e-Book to be ... the exceptional women featured in the series’ third book, ... title of the upcoming mini e-Book is Ingredients ... is currently a full-time physician’s assistant, and mother of ... Raising Sextuplets. , Jenny was chosen as an outlier ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Beginning Tuesday, ... over 3,000 medical professionals and 10,000 consumers for the ... a 5-day gathering of the nation’s top medical professionals ... diseases or conditions. The week-long event contains more than ... scientific instruction available in the pain management field. , ...
(Date:8/31/2014)... Washington, D.C.USA (PRWEB) August 31, 2014 ... the global community utilizing social media marketing tools ... and interactive programs. MMU will utilize all tools ... become learning partner for our multiple learning channels. ... new mobile app, and an authoring tool that ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 2Health News:My Mobile University Announces Global Strategic Plan and Unveils New Android App to Enhance and Impact Lives World-Wide Through Education for All as Learning Platform 3
... recently introduced at the Summer American Academy ... the treatment of mild-to-moderate atopic dermatitis in ... the marketers of Locoid Lipocream (hydrocortisone butyrate ... recently launched the new product to cover ...
... evidence that some people with HIV who for years and ... their blood never progress to full-blown AIDS and remain symptom ... strength of their immune systems, not any defects in the ... , Their conclusions about so-called elite suppressors, published ...
... Pa., Aug. 11 MEDRAD, INC., announced today,that ... System has received,U.S. Food and Drug Administration (FDA) ... The new Continuum Wireless MR Infusion System ... during a magnetic resonance (MR),procedure from both inside ...
... Tenn., Aug. 11 TeamHealth Inc.,s parent,company, Team ... the,second quarter ended June 30, 2008., The ... anesthesia,management services business line and substantially completed the ... of 2007. In accordance with,relevant accounting guidance, the ...
... Could Help Prevent,Another Blood Crisis, Allow More New Yorkers ... Has 35!!!, NEW YORK, Aug. 11 With ... New York City Councilman Eric Gioia,(D-Queens), Chairman of the ... New York Blood Center called for city,aid in expanding ...
... BEIJING, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. ... that it,intends to offer, subject to market and ... senior notes due 2013 and,American Depositary Shares, or ... underwriters of the notes offering pursuant to ADS,issuance ...
Cached Medicine News:Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 2Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 3Health News:Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1% 4Health News:Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs 2Health News:Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs 3Health News:MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System 2Health News:MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System 3Health News:Team Finance LLC Announces Second Quarter 2008 Results 2Health News:Team Finance LLC Announces Second Quarter 2008 Results 3Health News:Team Finance LLC Announces Second Quarter 2008 Results 4Health News:Team Finance LLC Announces Second Quarter 2008 Results 5Health News:Team Finance LLC Announces Second Quarter 2008 Results 6Health News:Team Finance LLC Announces Second Quarter 2008 Results 7Health News:Team Finance LLC Announces Second Quarter 2008 Results 8Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 2Health News:Gioia & New York Blood Center Call for City Aid in Expansion of Mobile Blood Donor Coach Program 3Health News:China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements 2Health News:China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements 3Health News:China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements 4
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... sulfate ester of DHEA, derived from sulfated ... in adrenal and extradrenal tissues. DHEA is ... adrenal cortex, and is a precursor for ... weak androgenic activity, which for unsulfated DHEA ...
Inquire...
Medicine Products: